C2N Diagnostics LLC, a St. Louis-based biotechnology firm that created a blood test designed to help doctors detect Alzheimer's disease, has added to its executive team with roles focused on commercialization and strategic partnerships.
C2N said this week it has hired Ozgur Sensoy as senior vice president of commercial operations and Daniel Connell as head of strategic alliances. The leadership additions come as C2N recently has brought on new funding and shared research results it says “demonstrate the accuracy” of its blood tests.
Founded in 2007, C2N Diagnostics has developed the PrecivityAD blood test, which is used by doctors to assist with diagnosis of Alzheimer's disease. C2N rolled out the test in 2020 and has billed itself as the first company to offer a widely accessible blood test for the disease. C2N in February said it has raised $15 million in funding to enhance its technology, with the capital being used for development of PrecivityAD2, a second version of its blood test.
Sensoy, in his role as senior vice president of commercial operations, will oversee C2N’s product portfolio and focus on bolstering its sales and marketing operations as the company seeks to expand access to its blood tests, C2N said in a news release. Sensoy joins C2N from Secaucus, New Jersey-based Quest Diagnostics, where he was head of U.S. specialty genetics. He’s also previously held roles at health care company Sanofi (NASDAQ: SNY) and Bayer Pharmaceuticals.
C2N said Connell’s role as head of strategic alliances will put a priority on managing its global partnerships with Australian health care company Healius Ltd. and Brazilian health care firm Group Fleury. Connell’s role also will focus on additional global expansion and forming relationships with biopharmaceutical companies, C2N said. Connell most recently worked for biopharmaceutical company AstraZeneca (NASDAQ: AZN) as senior director of computational pathology strategy in oncology R&D.
“Ozgur and Daniel further complement our dynamic team’s ability to create a vision to bring the best-in-class diagnostic and therapeutic monitoring biomarkers in the industry to patients, providers, researchers, and biotherapeutic developers seeking to transform the trajectory of Alzheimer’s disease and brain health, in general,” Joel Braunstein, president and CEO of C2N, said in a statement. "We are thrilled that they see the same vision we see and are dedicating the next phase of their careers to enable us to achieve our goals and ambitions.”
C2N has its headquarters at the BioSTL Building at 4340 Duncan Ave. in the Cortex innovation district. It also operates a R&D lab nearby at 20 S. Sarah St.
